Dynavax Technologies Corporation is a drug manufacturers - specialty & generic business based in the US. Dynavax Technologies Corporation shares (DVAX) are listed on the NASDAQ and all prices are listed in US Dollars. Dynavax Technologies Corporation employs 408 staff and has a trailing 12-month revenue of around $236.1 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $10.95 |
|---|---|
| 52-week range | $10.23 - $15.15 |
| 50-day moving average | $11.35 |
| 200-day moving average | $12.62 |
| Wall St. target price | $25.75 |
| PE ratio | 146.4286 |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $0.07 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $10.95 from 2024-07-23
| 1 week (2024-07-17) | 2.62% |
|---|---|
| 1 month (2024-06-24) | -3.95% |
| 3 months (2024-04-24) | -4.12% |
| 6 months (2024-01-24) | -21.45% |
| 1 year (2023-07-24) | -22.94% |
|---|---|
| 2 years (2022-07-22) | -25.91% |
| 3 years (2021-07-23) | 15.63% |
| 5 years (2019-07-24) | 253.23% |
Valuing Dynavax Technologies Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Dynavax Technologies Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Dynavax Technologies Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 146x. In other words, Dynavax Technologies Corporation shares trade at around 146x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
| Revenue TTM | $236.1 million |
|---|---|
| Gross profit TTM | $448.2 million |
| Return on assets TTM | -1.35% |
| Return on equity TTM | 1.56% |
| Profit margin | 3.9% |
| Book value | $4.73 |
| Market Capitalization | $1.3 billion |
TTM: trailing 12 months
We're not expecting Dynavax Technologies Corporation to pay a dividend over the next 12 months.
Dynavax Technologies Corporation's shares were split on a 1:10 basis on 9 November 2014. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Dynavax Technologies Corporation shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Dynavax Technologies Corporation shares which in turn could have impacted Dynavax Technologies Corporation's share price.
Over the last 12 months, Dynavax Technologies Corporation's shares have ranged in value from as little as $10.23 up to $15.15. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Dynavax Technologies Corporation's is 1.276. This would suggest that Dynavax Technologies Corporation's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc. ; Clover Biopharmaceuticals (Hong Kong) Co. , Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt.
Trade commission-free stocks and ETFs with Opto, and stay ahead by spotting emerging trends through thematic investing.
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
Learn the basics of put options: what they are, how they work and a few examples.
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
These are the best day trading platforms, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Looking for a discount broker like Webull that offers something different? Here are some of the top alternatives to consider.
What you need to know about investing in the leading indicator for the overall US stock market.
Check out our 7 ideas for how to invest $10K to maximize your money.
Check out the best-performing ETFs so far in 2024.